Now showing items 1-20 of 21

    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment 

      Flores-Borja, F; Irshad, S; Gordon, P; Wong, F; Sheriff, I; Tutt, A; Ng, T (2016)
    • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

      Natrajan, R; Tutt, ANJ; Lord, CJ (2018-03)
      <b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...
    • E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. 

      Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)
      The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...
    • Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. 

      Naidoo, K; Wai, PT; Maguire, SL; Daley, F; Haider, S; Kriplani, D; Campbell, J; Mirza, H; Grigoriadis, A; Tutt, A; Moseley, PM; Abdel-Fatah, TMA; Chan, SYT; Madhusudan, S; Rhaka, EA; Ellis, IO; Lord, CJ; Yuan, Y; Green, AR; Natrajan, R (2018-01)
      Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. ...
    • Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. 

      Lawler, K; Papouli, E; Naceur-Lombardelli, C; Mera, A; Ougham, K; Tutt, A; Kimbung, S; Hedenfalk, I; Zhan, J; Zhang, H; Buus, R; Dowsett, M; Ng, T; Pinder, SE; Parker, P; Holmberg, L; Gillett, CE; Grigoriadis, A; Purushotham, A (2017-10-13)
      BACKGROUND: Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are ...
    • Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph nodepositive breast cancers 

      Grigoriadis, A; Gazinska, P; Pai, T; Irhsad, S; Wu, Y; Millis, R; Naidoo, K; Owen, J; Gillett, C; Tutt, A; Coolen, A; Pinder, S
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. 

      Davies, H; Glodzik, D; Morganella, S; Yates, LR; Staaf, J; Zou, X; Ramakrishna, M; Martin, S; Boyault, S; Sieuwerts, AM; Simpson, PT; King, TA; Raine, K; Eyfjord, JE; Kong, G; Borg, Å; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Børresen-Dale, A-L; Martens, JWM; Span, PN; Lakhani, SR; Vincent-Salomon, A; Sotiriou, C; Tutt, A; Thompson, AM; Van Laere, S; Richardson, AL; Viari, A; Campbell, PJ; Stratton, MR; Nik-Zainal, S (2017-04)
      Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic ...
    • Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. 

      Patel, N; Weekes, D; Drosopoulos, K; Gazinska, P; Noel, E; Rashid, M; Mirza, H; Quist, J; Brasó-Maristany, F; Mathew, S; Ferro, R; Pereira, AM; Prince, C; Noor, F; Francesch-Domenech, E; Marlow, R; de Rinaldis, E; Grigoriadis, A; Linardopoulos, S; Marra, P; Tutt, ANJ (2018-03-13)
      Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies ...
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

      Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, SM; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GK; Jang, SJ; Jones, DR; Kim, HY; King, TA; Krishnamurthy, S; Lee, HJ; Lee, JY; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BK; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JW; Børresen-Dale, AL; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
      We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
    • Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. 

      Denkert, C; Liedtke, C; Tutt, A; von Minckwitz, G (2017-06-17)
      Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ...
    • Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. 

      Coles, CE; Griffin, CL; Kirby, AM; Titley, J; Agrawal, RK; Alhasso, A; Bhattacharya, IS; Brunt, AM; Ciurlionis, L; Chan, C; Donovan, EM; Emson, MA; Harnett, AN; Haviland, JS; Hopwood, P; Jefford, ML; Kaggwa, R; Sawyer, EJ; Syndikus, I; Tsang, YM; Wheatley, DA; Wilcox, M; Yarnold, JR; Bliss, JM; IMPORT Trialists (2017-09-09)
      BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that ...
    • PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. 

      Brasó-Maristany, F; Filosto, S; Catchpole, S; Marlow, R; Quist, J; Francesch-Domenech, E; Plumb, DA; Zakka, L; Gazinska, P; Liccardi, G; Meier, P; Gris-Oliver, A; Cheang, MCU; Perdrix-Rosell, A; Shafat, M; Noël, E; Patel, N; McEachern, K; Scaltriti, M; Castel, P; Noor, F; Buus, R; Mathew, S; Watkins, J; Serra, V; Marra, P; Grigoriadis, A; Tutt, AN (2016-11)
      Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets of patients with TNBC. TNBC ...
    • RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers 

      Irshad, S; Flores-Borja, F; Lawler, K; Monypenny, J; Evans, R; Male, V; Gordon, P; Cheung, A; Gazinska, P; Noor, F; Wong, F; Grigoriadis, A; Fruhwirth, GO; Barber, PR; Woodman, N; Patel, D; Rodriguez-Justo, M; Owen, J; Martin, SG; Pinder, SE; Gillett, CE; Poland, SP; Ameer-Beg, S; McCaughan, F; Carlin, LM; Hasan, U; Withers, DR; Lane, P; Vojnovic, B; Quezada, SA; Ellis, P; Tutt, ANJ; Ng, T (2017-03-01)
    • RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers 

      Irshad, S; Flores-Borja, F; Lawler, K; Monypenny, J; Evans, R; Male, V; Gordon, P; Cheung, A; Gazinska, P; Noor, F; Wong, F; Grigoriadis, A; Fruhwirth, GO; Barber, PR; Woodman, N; Patel, D; Rodriguez-Justo, M; Owen, J; Martin, SG; Pinder, SE; Gillett, CE; Poland, SP; Ameer-Beg, S; McCaughan, F; Carlin, LM; Hasan, U; Withers, DR; Lane, P; Vojnovic, B; Quezada, SA; Ellis, P; Tutt, ANJ; Ng, T (2017-03-01)
    • Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. 

      Ju, YS; Martincorena, I; Gerstung, M; Petljak, M; Alexandrov, LB; Rahbari, R; Wedge, DC; Davies, HR; Ramakrishna, M; Fullam, A; Martin, S; Alder, C; Patel, N; Gamble, S; O'Meara, S; Giri, DD; Sauer, T; Pinder, SE; Purdie, CA; Borg, Å; Stunnenberg, H; van de Vijver, M; Tan, BKT; Caldas, C; Tutt, A; Ueno, NT; van 't Veer, LJ; Martens, JWM; Sotiriou, C; Knappskog, S; Span, PN; Lakhani, SR; Eyfjörd, JE; Børresen-Dale, A-L; Richardson, A; Thompson, AM; Viari, A; Hurles, ME; Nik-Zainal, S; Campbell, PJ; Stratton, MR (2017-03-30)
      Somatic cells acquire mutations throughout the course of an individual's life. Mutations occurring early in embryogenesis are often present in a substantial proportion of, but not all, cells in postnatal humans and thus ...
    • Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. 

      Gracio, F; Burford, B; Gazinska, P; Mera, A; Mohd Noor, A; Marra, P; Gillett, C; Grigoriadis, A; Pinder, S; Tutt, A; de Rinaldis, E (2017-01-06)
      Despite advancements in the use of transcriptional information to understand and classify breast cancers, the contribution of splicing to the establishment and progression of these tumours has only recently starting to ...
    • Tandem duplications contribute to not one but two distinct phenotypes. 

      Watkins, J; Tutt, A; Grigoriadis, A (2016-09)
    • Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. 

      Koo, C-Y; Giacomini, C; Reyes-Corral, M; Olmos, Y; Tavares, IA; Marson, CM; Linardopoulos, S; Tutt, AN; Morris, JDH (2017-11)
      Thousand-and-one amino acid kinases (TAOK) 1 and 2 are activated catalytically during mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize a compound that inhibits TAOK1 and ...